#### Sex differences, cross-ancestry generalizability, and noise-smoking interactions 1

#### in the polygenic architecture of hearing loss in adults 2

- 3
- Flavio De Angelis<sup>1,2</sup>, Oana A. Zeleznik<sup>3,4</sup>, Frank R. Wendt<sup>1,2</sup>, Gita A. Pathak<sup>1,2</sup>, Daniel S. Tylee<sup>1,2</sup>, 4
- Antonella De Lillo<sup>1,5</sup>, Dora Koller<sup>1,2,6</sup>, Brenda Cabrera-Mendoza<sup>1,2</sup>, Royce E Clifford<sup>7,8</sup>, Adam X. 5
- Maihofer<sup>8,9,10</sup>, Caroline M. Nievergelt<sup>8,9,10</sup>, Gary C. Curhan<sup>3,4</sup>, Sharon G. Curhan<sup>3,4</sup>, Renato 6
- Polimanti<sup>1,2\*</sup> 7
- 8
- 9 1. Department of Psychiatry, Yale University School of Medicine, West Haven, Connecticut, USA
- 2. Veteran Affairs Connecticut Healthcare System, West Haven, Connecticut, USA 10
- 3. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's 11
- Hospital, Boston, Massachusetts, USA 12
- 4. Harvard Medical School, Boston, Massachusetts, USA 13
- 5. Department of Biology, University of Rome "Tor Vergata", Rome, Italy 14
- 6. Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of 15 Barcelona, Spain 16
- 7. Division of Otolaryngology, Department of Surgery, University of California, San Diego, La 17 Jolla, California, USA 18
- 8. Research Service, Veterans Affairs San Diego Healthcare System, San Diego, California, USA 19
- 20 9. Department of Psychiatry, University of California, San Diego, La Jolla, California, USA
- 21 10. Center of Excellence for Stress and Mental Health, Veterans Affairs San Diego Healthcare
- System, San Diego, California, USA. 22
- 23
- 24
- 25
- 26
- \*Correspondence to: Renato Polimanti, PhD. Yale University School of Medicine, Department of 27
- 28 Psychiatry. VA CT 116A2, 950 Campbell Avenue, West Haven, CT 06516, USA. Phone: +1 (203)
- 932-5711 x5745. Fax: +1 (203) 937-3897. E-mail: renato.polimanti@yale.edu. ORCID: 0000-0003-29
- 0745-6046. 30
- 31

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 32 Abstract

We conducted a comprehensive genome-wide investigation of hearing loss (HL) in 748,668 adult 33 participants of the UK Biobank, the Nurses' Health Studies (I and II), the Health Professionals 34 Follow-up Study, and the Million Veteran Program. We identified 54 risk loci and characterized HL 35 polygenic architecture, exploring sex differences, polygenic risk across ancestries, tissue-specific 36 transcriptomic regulation, cause-effect relationships with genetically-correlated traits, and gene 37 interactions with HL environmental risk factors. Our transcriptomic regulation analysis highlighted 38 the potential role of the central nervous system in HL pathogenesis. This was supported by the 39 multivariate interaction analysis that showed how genes involved in brain development interact with 40 sex, noise pollution, and tobacco smoking in relation to their HL associations. Additionally, the 41 42 genetically-informed causal inference analysis showed that HL is linked to many physical and mental health outcomes. These results provide many novel insights into the complex biology and 43 epidemiology of HL in adults. 44

45

46

47

# 48 INTRODUCTION

Acquired hearing loss (HL) is the third most common chronic health condition<sup>1</sup> and the fourth 49 leading cause of disability globally<sup>2</sup>. The World Health Organization (WHO) report of hearing 50 projects that nearly 2.5 billion individuals will have some degree of HL by 2050<sup>3</sup>. HL is associated 51 with several comorbid conditions<sup>4</sup>. For instance, HL-induced impaired communication ability 52 particularly among older people can lead to social isolation with major health, psychosocial, and 53 economic consequences, reducing the quality of life<sup>4,5</sup>. HL affects individuals of all ages, but its 54 prevalence increases with age, reflecting the cumulative effect of environmental factors and genetic 55 predisposition<sup>6</sup>. 56

57

Heritability estimates for acquired HL range from 30% up to 70%<sup>7</sup>, highlighting that genetic 58 59 variation is a key determinant for individual HL risk. More than 100 genes present mutations that result in congenital HL not associated with disorders in other organs or dysmorphic features (non-60 syndromic HL)<sup>8,9</sup>. Mutations causing congenital HL affect genes involved in cochlear function, 61 specifically affecting the sensory and mechanosensory cells $^{10-12}$ . Beyond these Mendelian forms, 62 acquired HL cases appear to be due to the additive effect of many common genetic variants with 63 small individual effects. Large-scale genome-wide association studies (GWAS) conducted in 64 population-based cohorts have identified more than 50 common risk variants and characterized the 65 regulatory role of these loci in multiple cell and tissue types  $^{13-16}$ . Although these studies have 66 generated important insights into the genetic predisposition to HL, there are several aspects of the 67 HL pathogenesis that are currently under-investigated by genetic studies. For instance, HL among 68 older adults is more common, more severe, and with earlier onset in men than in women, even after 69 adjusting for confounding factors such as higher occupational noise exposure in men<sup>17,18</sup>. However, 70 the molecular pathways that underlie HL sex differences are unclear. Similarly, we have a limited 71 72 understanding which are the biological processes interacting with HL environmental risk factors. Several studies showed that noise pollution and tobacco smoking are HL risk factors<sup>19–22</sup>, but to 73

date no large-scale studies investigated how genetic variation interacts with noise pollution and
tobacco smoking in determining HL risk.

76

77	In the present study, we conducted an extensive genome-wide investigation across the UK Biobank
78	(UKB; 251,233 women and 214,549 men) <sup>14</sup> , the Nurses' Health Studies (NHS I, 14,978 women;
79	and NHS II, 12,533 women) <sup>23,24</sup> and the Health Professionals Follow-up Study (HPFS, 8,532
80	men) <sup>25</sup> . The risk loci identified were replicated in a sample of 226,043 participants from the Million
81	Veteran Program (MVP) <sup>26</sup> . Our findings provide a more comprehensive understanding of the
82	genetic basis of HL sex differences, uncovering novel sex-specific risk loci, molecular processes,
83	putative cause-effect relationships, and the interaction of genetic variation with sex, noise pollution,
84	and smoking behaviors.
85	
86	METHODS
87	Cohorts and hearing-loss assessment
87 88	<b>Cohorts and hearing-loss assessment</b> We leveraged genome-wide information from 748,668 adult participants recruited by the UKB,
87 88 89	Cohorts and hearing-loss assessment We leveraged genome-wide information from 748,668 adult participants recruited by the UKB, NHS I, NHS II, HPFS, and MVP cohorts to investigate the polygenic architecture of HL.
87 88 89 90	Cohorts and hearing-loss assessment         We leveraged genome-wide information from 748,668 adult participants recruited by the UKB,         NHS I, NHS II, HPFS, and MVP cohorts to investigate the polygenic architecture of HL.         UKB is a large population-based research resource, containing in-depth genetic and health
87 88 89 90 91	Cohorts and hearing-loss assessment We leveraged genome-wide information from 748,668 adult participants recruited by the UKB, NHS I, NHS II, HPFS, and MVP cohorts to investigate the polygenic architecture of HL. UKB is a large population-based research resource, containing in-depth genetic and health information from over 500,000 UK participants 40-69 years at enrollment <sup>14</sup> . UKB HL-related
87 88 89 90 91 92	Cohorts and hearing-loss assessmentWe leveraged genome-wide information from 748,668 adult participants recruited by the UKB,NHS I, NHS II, HPFS, and MVP cohorts to investigate the polygenic architecture of HL.UKB is a large population-based research resource, containing in-depth genetic and healthinformation from over 500,000 UK participants 40-69 years at enrollment <sup>14</sup> . UKB HL-relatedphenotypes were defined by self-reported items derived from a touchscreen questionnaire and
87 88 90 91 92 93	Cohorts and hearing-loss assessment We leveraged genome-wide information from 748,668 adult participants recruited by the UKB, NHS I, NHS II, HPFS, and MVP cohorts to investigate the polygenic architecture of HL. UKB is a large population-based research resource, containing in-depth genetic and health information from over 500,000 UK participants 40-69 years at enrollment <sup>14</sup> . UKB HL-related phenotypes were defined by self-reported items derived from a touchscreen questionnaire and audiometric measurements assessed through the Speech Recognition Threshold (SRT) test. The
87 88 90 91 92 93 94	Cohorts and hearing-loss assessmentWe leveraged genome-wide information from 748,668 adult participants recruited by the UKB, NHS I, NHS II, HPFS, and MVP cohorts to investigate the polygenic architecture of HL.UKB is a large population-based research resource, containing in-depth genetic and health information from over 500,000 UK participants 40-69 years at enrollment <sup>14</sup> . UKB HL-related phenotypes were defined by self-reported items derived from a touchscreen questionnaire and audiometric measurements assessed through the Speech Recognition Threshold (SRT) test. The self-reported items included the following binary traits: "Do you have any difficulty with your
87 88 90 91 92 93 94 95	Cohorts and hearing-loss assessment We leveraged genome-wide information from 748,668 adult participants recruited by the UKB, NHS I, NHS II, HPFS, and MVP cohorts to investigate the polygenic architecture of HL. UKB is a large population-based research resource, containing in-depth genetic and health information from over 500,000 UK participants 40-69 years at enrollment <sup>14</sup> . UKB HL-related phenotypes were defined by self-reported items derived from a touchscreen questionnaire and audiometric measurements assessed through the Speech Recognition Threshold (SRT) test. The self-reported items included the following binary traits: "Do you have any difficulty with your hearing?" (UKB Field ID: 2247); "Do you find it difficult to follow a conversation if there is

97 *a hearing aid most of the time?*" (UKB Field ID: 3393). UKB participants who indicated they were

completely deaf (N=144) were excluded from the analysis to reduce the likelihood of including

99 congenital forms of  $HL^{16}$ . For ~12% of the UKB participants (59,807 for UKB Field ID 2247;

100 60,448; and 40,656 for UKB Field ID 3393), these items were assessed multiple times. Since age is 101 a strong risk factor for acquired HL, we considered the most recent assessment when multiple assessments were available to improve the ability to detect the disease onset. In addition to 102 considering these binary traits individually, we combined them in a four-category ordinal phenotype 103 104 (Supplemental Table 1). For the SRT-derived audiometric measurements, we considered the UKB item "the signal-to-noise ratio at which half of the presented speech can be understood correctly" 105 for both left and right ears (UKB Field ID: 20019 and 20021, respectively). Because of the much 106 larger sample size, we included unrelated UKB participants of European descent in the primary 107 discovery sample. The other ancestry groups available in UKB were used for single-variant and 108 109 polygenic risk score (PRS) replication (see section Cross-ancestry Replication and Polygenic Risk 110 Scoring).

111

Additional genome-wide information was derived from NHS I, NHS II, and HPFS cohorts. The 112 NHS I began in 1976 when 121,700 female registered nurses, aged 30–55 years, were enrolled by 113 completing a baseline questionnaire about their health and lifestyle. In 1989, the NHS II was 114 established and enrolled 116,429 younger female registered nurses, aged 25 to 42 years<sup>24</sup>. The 115 HPFS began in 1986 and enrolled 51,529 male health professionals, aged 40 to 75 years. In each of 116 117 the cohorts, detailed information on demographics, health, diet, and lifestyle factors was collected and updated every 2 years (every 4 years for diet). The follow-up rates in all 3 cohorts exceed 90% 118 of eligible person-time<sup>27</sup>. Self-reported hearing status was determined based on participants' 119 responses to biennial questionnaires. "Hearing difficulty" was defined as a participant report of a 120 hearing problem that was mild, moderate, severe (non-hearing aid user), or severe (hearing aid 121 user). Leveraging samples with genome-wide information, we investigated 14,978 unrelated female 122 NHS I participants, 12,533 unrelated female NHS II participants, and 8,532 unrelated male HPFS 123 participants, all of European descent. To maximize the sample size available, we meta-analyzed 124 125 NHS I and II cohorts and referred to them hereafter as a single NHS sample.

126

The MVP is a biobank funded by the US Department of Veterans Affairs that to date enrolled more
than 800,000 participants among active users of the Veterans Health Administration healthcare
system<sup>26</sup>. In our analysis, we used genome-wide information regarding 85,743 cases and 140,300
controls based on self-reported hearing-loss information. Information regarding HL assessment in
MVP has been previously described <sup>28</sup>.

132

# 133 Genome-wide data quality control and GWAS meta-analysis

We used UKB imputed data  $^{29}$ , filtering variants with imputation score < 0.8, minor allele 134 frequency (MAF) < 0.01, Hardy-Weinberg Equilibrium p-values  $<10^{-6}$ , and missingness > 0.1. The 135 genetic data were employed to identify related individuals by estimating kinship coefficients for all 136 pairs of samples. Accordingly, we removed individuals based on relatedness (one individual from 137 pairs with kinship coefficient > 0.042 was removed, with the preference to retain cases), forming a 138 maximally unrelated subset<sup>29</sup>. In the NHS and HPFS cohorts, SNPs with imputation score <0.8 or 139 minor allele frequency < 0.05 were excluded. Quality checks included the exclusion of those 140 participants with a poor genotype call rate (<95%) and a check for relatedness. The SNPs with a 141 poor call rate (<95%), out of Hardy-Weinberg equilibrium (P $<10^{-5}$ ), with high duplicate 142 discordance rates, or monomorphic were excluded. Genotyped data from each of the NHS and 143 HPFS studies were imputed using the 1000 Genomes Project Phase 3 reference panel <sup>30,31</sup>. Details 144 regarding genotyping and imputation of the MVP samples were described elsewhere<sup>32</sup>. Relatedness 145 was estimated using KING<sup>33</sup>. For each pair of subjects with an estimated kinship coefficient > 0.088146 (2nd degree or closer), one individual was removed, with the preference to retain cases. If 147 individuals had the same diagnostic status, one individual was removed at random. HARE 148 (harmonized ancestry and race/ethnicity) estimates<sup>34</sup> were used to select European ancestry 149 individuals. GWAS were carried out in the UKB, NHS, and HPFS by logistic regression, using 150 PLINK 2.0<sup>35</sup> and including age and the first 10 within-ancestry PCs as covariates. For the sex-151

combined analyses, sex was also included as a covariate. The GWAS generated by the individual
 cohorts were meta-analyzed using the inverse variance-based method implemented in METAL<sup>36</sup>. In
 MVP, GWAS was performed using logistic regression of the hearing phenotype on imputed SNP
 dosages including covariates for 10 PCs, age, and sex, using PLINK 1.9 software<sup>35</sup>.

156

# 157 SNP-based heritability and genetic correlation

SNP-based heritability (SNP-h<sup>2</sup>) and genetic correlation (rg) for all hearing traits were estimated 158 using the Linkage Disequilibrium Score Regression (LDSC) method<sup>37</sup>. As recommended by the 159 LDSC developers (details at https://github.com/bulik/ldsc), the analysis was conducted considering 160 161 the HapMap 3 reference panel and pre-computed LD scores based on the 1000 Genomes Project reference data for individuals of European ancestry. SNP-h<sup>2</sup> and genetic correlations were evaluated 162 among HL trait assessed in the UKB, NHS, HPFS, and their meta-analyses. Since functional 163 categories of the genome contribute disproportionately to the heritability of complex diseases<sup>38</sup>, 164 SNP-h<sup>2</sup> partitioning was conducted with LDSC using 95 baseline genomic annotations<sup>39</sup> such as 165 allele frequency distributions, conserved genomic regions, regulatory elements, and annotations for 166 genic, loss-of-function (LoF) intolerant, positively and negatively selected regions<sup>40</sup>. We also 167 conducted a UKB phenome-wide genetic correlation analysis of HL, testing 7,153 phenotypes for 168 169 the sex-combined investigation, 3.287 phenotypes for the female-specific investigation, and 3.144 phenotypes for the male-specific investigation. The genome-wide association statistics for the sex-170 combined analysis were derived from the Pan-UKB data release (available at 171 https://pan.ukbb.broadinstitute.org/downloads). The sex-specific genome-wide association statistics 172 were derived from a previous UKB analysis (available at http://www.nealelab.is/uk-biobank). 173 174

# 175 Latent causal variable analysis

To evaluate whether the genetic correlations of HL are due to cause-effect relationships, we usedthe latent causal variable (LCV) method to conduct a genetically-informed causal inference

analysis<sup>41</sup>. As recommended, only SNPs with MAF > 5% were considered, and the major histocompatibility region was removed. Considering traits that reached at least a nominally significant genetic correlation (p<0.05) with HL, we tested 879 traits in the sex-combined analysis, 323 traits in the female-specific analysis, and 332 traits in the male-specific analysis. For each comparison, the genetic causality proportion (gcp) can range from zero (no partial genetic causality) to one (full genetic causality).

184

Variant prioritization, fine-mapping, and multi-tissue transcriptome-wide association study 185 To identify the causal loci underlying the statistical association observed, we functionally annotated 186 187 GWAS findings and prioritized the most likely causal SNPs and genes using pre-calculated LD structure based on 1000 Genomes Project EUR reference populations<sup>42</sup>. The risk loci identified in 188 the sex-combined and sex-specific meta-analyses were classified considering the following 189 190 parameters derived from Functional Mapping and Annotation of Genome-Wide Association Studies  $(FUMA)^{42}$ : leadP = 5×10<sup>-8</sup>; gwasP = 0.05; R<sup>2</sup> = 0.1; refpanel = 1000 Genomes Project Phase3 EUR 191 192 reference populations; MAF = 0.01; refSNPs = 1; mergeDist = 250. Positional mapping was performed considering MapWindowSize = 10 and the minimum Combined Annotation Dependent 193 Depletion (CADD)<sup>43</sup> score for SNP filtering was set to 0. Gene-based analysis and gene-set analysis 194 were performed with Multi-marker Analysis of GenoMic Annotation (MAGMA)<sup>44</sup> integrated into 195 FUMA. Tissue enrichment analysis was performed using Genotype-Tissue Expression (GTEx) 196 project v8 data<sup>45</sup>. 197

We fine-mapped the association statistics for a 3MB region around the lead SNP of the genomic risk locus identified by FUMA ( $r^2 = 0.1$ ; window = 250bp). Each region for the respective association was fine-mapped to determine 95% credible set using susieR<sup>46</sup> with at most 10 causal variants (default). The credible set reports variants most likely to be causal based on the marginal posterior inclusion probability (PIP) ranging from 0 to 1, with values closer to 1 to be most causal.

203 To further explore transcriptomic regulation in the context of HL, we performed a multi-tissue

204 TWAS (transcriptome-wide association study), using the S-MultiXcan approach to combine

information across 49 GTEx tissues adjusting for tissue-tissue correlation $^{47}$ .

206

#### 207 Cross-ancestry replication and polygenic risk scoring

208 We used data from the Pan-UKB data release (available at

209 https://pan.ukbb.broadinstitute.org/downloads) to conduct cross-ancestry replication and PRS

analyses. Specifically, we derived PRS of HL associations from EUR ancestry (base dataset) and

tested in UKB participants of African (AFR N=6,636), admixed American (AMR N=980),

212 Centra/South Asian (CSA N=8,876), East Asian (EAS N=2,709), and Middle Eastern (MID

213 N=1,599) ancestries (target datasets). PRS analysis based on HL meta-analyzed and sex-stratified

GWAS was computed using PRSice v.  $2.3.1.c^{48}$ , using the clumping-thresholding method to

maximize the predictive ability of the derived polygenic scores<sup>49</sup>. Using 1000 Genomes Project

EUR populations as reference panel, SNPs were clumped based on 250kb windows, based on

clump-r2 threshold=0.1 and clump-p threshold=1, respectively. The step size of the threshold was

set to  $5 \times 10^{-5}$ , and the range of p-value thresholds was from  $5 \times 10^{-8}$  to p=1 using an additive model

219 for regression at each threshold.

220

### 221 Multivariate gene-by-environment genome-wide interaction study

A multivariate gene-by-environment genome-wide interaction study (GEWIS) was performed using StructLMM<sup>50</sup>, a linear mixed-model approach to efficiently detect interactions between loci and multiple potentially correlated environments. Since StructLMM assumes a quantitative trait, the GEWIS was conducted considering the four-category ordinal trait described above (Supplemental Table 1). The multivariate GEWIS was performed considering a total of 14 environments, including sex, smoking behaviors and exposures, and different types of noise pollution exposure (Supplemental Table 2). Marginal log-likelihoods (log (Bayes factor -BF)) between the full model

229	and the reduced model with environments removed were used to identify the most relevant
230	environments for the detected locus interaction effects. A pathway enrichment analysis was
231	conducted considering loci with nominally significant multivariate gene-environment interaction.
232	These variants were clumped using R ld_clump function (ieugwasr R package) using clump_kb =
233	10,000, $clump_r2 = 0.001$ , and $clump_p = 0.05$ . The resulting variants showing BF>1 were mapped
234	to genes through Ensembl platform <sup>51</sup> . A Gene Ontology (GO) enrichment analysis was performed
235	using the Database for Annotation, Visualization and Integrated Discovery (DAVID) <sup>52</sup> and GO
236	terms surviving false discovery rate (FDR) multiple testing correction (q< $0.05$ ) were retained as
237	significant.

238

#### 239 **RESULTS**

#### 240 SNP-based heritability and genetic correlation among hearing-loss traits

241 We investigated the SNP- $h^2$  across multiple HL traits. In the UKB, these included phenotypes derived

from the touchscreen questionnaire and an automated hearing assessment (i.e., SRT test). For the

questionnaire-derived HL traits, the SNP-h<sup>2</sup> ranged from 0.017±0.002 for "*Hearing aid use*" to

244 0.050±0.002 for "Hearing difficulties with background noise". The genome-wide statistics of these HL

traits were characterized by inflation due to polygenicity (genomic-control lambda>1.09) and not

because of possible confounders (LDSC intercept < 1.03; Supplemental Table 3). With respect to STR-

derived traits, the SNP- $h^2$  was lower <1% with only right-ear assessment with an estimate

- statistically different from zero (SRT-right SNP- $h^2 = 0.009 \pm 0.002$ ; Table 1). The limited
- informativeness of the SRT test in genetic studies is in line with previous findings $^{16,53}$ . Accordingly,

the SRT-derived traits were excluded for further evaluations.

- 251
- 252
- 253

254

The genetic correlations among the questionnaire-derived HL traits in UKB ranged from 255 256 rg=0.830±0.013 between "Hearing difficulties" and "Hearing difficulties with background noise", to rg=0.393±0.039 between "Hearing difficulties with background noise" and "Hearing aid use" 257 (Figure 1; Supplemental Table 4). 258 259 The ordinal phenotype derived from combining the three questionnaire-derived HL traits in UKB 260 261 (Supplemental Table 1; hereafter abbreviated as HL-ORD) showed a high genetic correlation with each of the binary phenotypes, ranging from  $rg=0.927\pm0.015$  with "Hearing difficulties" to 262 rg=0.830±0.020 with "Hearing aid use". 263 264 To further investigate the differences across the questionnaire-derived HL traits, we conducted a 265 sex-stratified analysis and tested the genetic correlation among whole-sample and sex-stratified 266 267 analyses in UKB and also with respect to HL assessed in NHS (female participants only; SNP $h^2=0.077\pm0.020$ ) and HPFS (male participants only; SNP- $h^2=0.161\pm0.053$ ). Considering each of 268 the HL traits tested, no difference was observed between sexes in the SNP-h<sup>2</sup> estimates (Table 1). 269 Among the UKB questionnaire-derived HL traits, "Hearing difficulties with background noise" 270 showed the highest rg between males and females (rg=0.882±0.035), while the lowest rg between 271 272 sexes was observed for the HL-ORD trait ( $rg=0.782\pm0.050$ ). 273

Considering the HPFS HL outcome and male-specific UKB analyses, the highest genetic
correlation was observed for *"Hearing difficulty"* (rg=0.633±0.136). The same trait was the one
with the highest genetic correlation with the NHS HL outcome among the UKB female-specific
analyses (rg=0.737±0.115). Based on the genetic correlations among UKB, HPFS, and NHS, the
UKB *"Hearing difficulties"* was defined as the primary UKB phenotype and the loci identified with
respect to this trait were tested for single-variant and PRS replication using the NHS and HPFS
datasets. Additionally, to maximize the discovery of our analyses, we also meta-analyzed UKB,

NHS, and HPFS cohorts (278,744 female participants from UKB and NHS and 223,081 male
participants from UKB and HPFS).

283

#### 284 Genome-wide association analyses

In UKB sex-combined analysis, we identified 46 LD-independent genome-wide significant (GWS)

loci ( $P < 5 \times 10^{-8}$ ) associated with hearing difficulties (Supplemental Table 5). In the sex-stratified

analyses, we identified 14 and 19 LD-independent GWS loci in males and females, respectively

288 (Supplemental Tables 6 and 7). In a few instances, the top-index variant identified in the sex-

stratified analyses was LD-independent from the ones mapped in the GWAS loci observed in the

entire cohorts. Additionally, we identified six variants with statistical differences in the sex-specific

effects of the HL-associated variants (Supplemental Tables 6 and 7; rs2876317 in *PDE7B*;

rs9784468 in *SORBS2*, rs1808828 in *ABLIM3*, rs9677089 in *SPTBN1*, rs12515096 in *ARHGEF28*,
and rs35624969 in *TBL2*).

Beyond single-variant associations, the PRS derived from UKB were significantly associated with hearing difficulties in NHS and HPFS considering sex-combined and sex-stratified analyses (sexcombined PRS on NHS+HPFS:  $R^2=0.05\%$ , p=6.59×10<sup>-6</sup>; female-specific PRS on NHS:  $R^2=0.47\%$ , p=1.77×10<sup>-30</sup>, male-specific PRS on HPFS:  $R^2=0.5\%$ , p=2.84×10<sup>-11</sup>).

298

The GWAS meta-analysis of UKB, NHS, and HPFS (N=501,825) provided a higher statistical
power, identifying 54 LD-independent loci significantly associated with hearing difficulties (Table
2).

302

303 In the sex-stratified investigation, we gained one additional locus in the male-specific GWAS meta-

analysis (15 LD-independent GWS loci) and five additional loci in the female-specific GWAS

305 meta-analysis (24 LD-independent GWS loci). Similar to the UKB-only GWAS, few index variants

306 identified in the sex-specific GWAS meta-analysis were LD-independent of the loci identified in

the overall GWAS meta-analysis and we identified statistical differences between sexes in their
effect size for three variants (Supplemental Table 8; rs13399656 mapped to *SPTBN1*, rs1808828 in *ABLIM3*, and rs11738813 in *ARHGEF28*).

Considering the 54 loci reaching genome-wide significance in the sex-combined meta-analysis, we 310 tested whether the effects detected were replicated in an independent sample, 226,043 MVP 311 participants of European descent. We observed that 34 loci were at least nominally replicated in the 312 313 MVP cohort (Table 2; p<0.05). Considering concordance between discovery and replication cohorts, 49 loci showed consistent effect direction. The probability of observing concordant 314 directions of 49 out of the 54 loci tested by chance is  $5.9 \times 10^{-6}$ . Leveraging our discovery GWAS 315 316 meta-analysis as a training dataset, we conducted a PRS analysis in the MVP cohort that showed highly significant prediction across all variant-inclusion thresholds tested ( $p<1.20\times10^{-103}$ ; 317

318 Supplemental Table 9).

319

To assess the cross-ancestry generalizability of the loci identified by the GWAS meta-analysis, we 320 conducted a replication analysis of the single-variant associations in the UKB participants of non-321 European descent (AFR N=6,636; AMR N=980; CSA N=8,876; EAS N=2,709; MID N=1,599). 322 Considering a nominal significance threshold, we replicated (p<0.05) the associations of four 323 variants (rs6675438, rs61863078, rs2273654, and rs61734651) in AFR, five variants (rs666720, 324 325 rs1220628, rs271143, rs9493627, rs146229052) in AMR, ten variants were replicated in CSA (rs666720, rs6662164, rs148512269, rs6869243, rs6871548, rs296430, rs2296506, rs766262445, 326 rs72930998, and rs1005473), and two variants in EAS (rs11238325, and rs34993346) 327 328 (Supplemental Table 10). The limited number of single-loci replication is due to the dramatic difference in sample size between the EUR discovery cohort (N=501,825) and the non-EUR 329 replication cohorts (total N=20,800). However, we observed a significant cross-ancestry 330 transferability in the HL PRS considering the GWAS meta-analysis and UKB-only GWAS as 331 training datasets. Specifically, we observed an increased statistical power of the PRS derived from 332

333	the GWAS meta-analysis (UKB-NHS-HPFS PRS: AFR $R^2$ =4.73%, p=4.65×10 <sup>-68</sup> ; AMR $R^2$ =1.96%,
334	$p=1.23\times10^{-5}$ ; CSA R <sup>2</sup> =3.5%, $p=6.26\times10^{-66}$ ; EAS R <sup>2</sup> =2.45%, $p=1.94\times10^{-15}$ ) when compared to the
335	one derived from the UKB-only GWAS (UKB-only PRS: AFR R <sup>2</sup> =0.14%, p=0.001; AMR
336	$R^2$ =0.54%, p=0.0140; CSA $R^2$ =0.13%, p=6.01×10 <sup>-4</sup> ; EAS $R^2$ =0.08, p=0.076). Due to the limited
337	sample size available, we did not conduct a sex-stratified cross-ancestry replication analysis with
338	respect to single-variant and PRS associations.

339

Because of the higher statistical power, the following sections describe the *in-silico* analyses
conducted on the basis of the GWAS meta-analyses of UKB (field ID 2247 "*Hearing difficulties*"),

342 NHS ("*Hearing problems*"), and HPFS ("*Hearing problems*").

343

344 Variant prioritization, fine-mapping, and multi-tissue transcriptome-wide association study
345 To translate genetic associations into information regarding potential causal genes associated with
346 hearing difficulties, we integrated different approaches ranging from positional mapping to
347 imputation of genetically-regulated transcriptomic variation.

348

First, we performed a fine-mapping analysis for each GWS locus. Based on the PIP of the 4,382 349 350 SNP associations reaching GWS in the sex-combined GWAS meta-analysis, we identified 218 variants that are most likely to be causal (PIP> 30%; Supplemental Figure 1). Considering a CADD 351 352 score threshold of 10 (top 1% of pathogenic variants across the human genome), we further 353 prioritized 24 variants that mapped to 18 unique genes (Supplemental Table 11). Some of them (e.g., ARID5B, CTBP2, and FTO) were previously identified as causal loci of Mendelian forms of 354 deafness and HL<sup>8,16</sup>. Applying the same mapping strategy to the sex-stratified GWS loci, we 355 identified 84 and 46 variants in the credible set for female- and male-specific analyses, respectively 356 (Supplemental Figures 2 and 3). These included six female-specific and two male-specific 357

358	pathogenic variants (CADD score>10). The sex-stratified mapping genes mostly overlapped with
359	the ones identified in the sex-combined GWAS meta-analysis.

360

361 In addition to the positional mapping approach, we also implemented an independent method based

362 on the genetic regulation of transcriptomic variation. Combining tissue-specific information

regarding expression quantitative trait loci (eQTL), we conducted a multi-tissue TWAS using the S-

MultiXcan approach<sup>47</sup>. In the sex-combined meta-analysis, we identified 107 transcriptome-wide

significant (TWS) genes (multi-tissue p< $2.24 \times 10^{-6}$ ; Figure 2; Supplemental Table 12).

366

Considering top tissue-specific effect underlying the cross-tissue associations, we observed that five 367 of the top-10 strongest associations were brain-related: putamen basal ganglia (*CRIP3*  $p=1.19\times10^{-10}$ 368 <sup>23</sup>), spinal cord c-1 (*PIK3R3* p= $1.32 \times 10^{-19}$ ), pituitary gland (*TMEM69* p= $2.14 \times 10^{-18}$ ), caudate basal 369 ganglia (*IPP*  $p=3.04\times10^{-18}$ ), cerebellar hemisphere (*SLC22A7*  $p=3.56\times10^{-18}$ ), and cerebellum 370 (*MAST2* p= $3.17 \times 10^{-17}$ ). The strongest non-brain related TWS associations included tibial artery 371 (ARHGEF28 p= $3.29 \times 10-17$ ), cultured fibroblasts (ACAN p= $5.17 \times 10^{-17}$ ), left ventricle (DLK2 372  $p=1.03\times10^{-16}$ ), and tibial nerve (*NASP*  $p=1.42\times10^{-16}$ ). In the sex-stratified meta-analysis, we 373 identified 55 and 26 multi-tissue TWS associations in females and males, respectively 374 (Supplemental Table 13). The sex-specific loci mostly overlapped with those identified in the sex-375 combined TWAS: i) 14 genes were TWS in three analyses; ii) 45 out of 55 female-specific TWS 376 377 genes were also significant in the sex-combined TWAS; iii) 23 out of the 26 male-specific TWS genes were also significant in the sex-combined TWAS. However, for tissue-specific effects, we 378 379 observed that the top genes were not related to brain transcriptomic regulation (top female-specific association: liver-*CRIP3*  $p=1.59\times10^{-18}$ ; top male-specific association: spleen-*PHLDB1*  $p=1.59\times10^{-18}$ 380 <sup>11</sup>). Additionally, among female-specific associations, we identified associations related to female 381 organs: mammary gland (ABCC10 p= $6.16 \times 10^{-15}$ ) and vagina (BAIAP2L2 p= $7.45 \times 10^{-13}$ ). 382

383

#### 384 Enrichment for regulatory elements and biological pathways

To dissect further its polygenic architecture, we partitioned HL SNP-h<sup>2</sup> with respect to regulatory 385 elements to uncover enrichment of relevant biological annotations and processes. We observed that 386 several annotations related to the regulatory function of the human genome are more likely to be 387 involved in HL predisposition than that expected by chance (Supplemental Table 14). These 388 included evolutionary-conserved regions (e.g., "genomic evolutionary rate profiling scores" 389  $p=1.11\times10^{-16}$ ) and "elements involved in epigenetic and transcriptomic regulation (e.g., "CpG 390 *dinucleotide content*"  $p=1.53\times10^{-10}$ ; *"super-enhancer regions*"  $p=1.54\times10^{-7}$ ). In a complementary 391 approach, we performed gene set enrichment analysis of HL-associated genes (based on 392 393 positionally mapping). Two biological pathways were observed to be statistically overrepresented: "response to trabected in" ( $p=1.58\times10^{-8}$ ) and "sensory perception of mechanical stimulus" 394  $(p=1.69\times10^{-7})$ . With respect to both analyses, we did not identify statistical differences in the 395 396 enrichments calculated from the sex-specific genetic associations. 397

### 398 Phenome-wide genetic correlation and latent causal variable analysis of hearing loss

To investigate the genetic overlap of HL with other traits and diseases, we assessed phenome-wide genetic correlation considering 5,337 phenotypes for the sex-combined analysis, 2,353 for the female-specific analysis, and 2,249 for the male-specific analysis. Considering a Bonferroni correction accounting for the number of phenotypes tested in sex-combined, female, and male analyses, we identified 309, 79, and 109 significant genetic correlations, respectively (Figure 3; Supplemental Table 15).

405

With respect to the sex-combined GWAS meta-analysis, the strongest genetic correlation was "*Tinnitus*" (rg=0.52, p=2.44×10<sup>-55</sup>). Other strong positive genetic correlations included "*Long standing illness, disability or infirmity*" (rg=0.36, p=7.12×10<sup>-41</sup>); and "*Frequency of tiredness / lethargy in last 2 weeks*" (rg= 0.33, p=3.85×10<sup>-37</sup>). Among negative HL genetic correlations, we

observed "Leisure/social activities" (rg=-0.19, P=3.30×10<sup>-10</sup>) and "Belief that own life is 410 *meaningful*" (rg=-0.18, p= $3.38 \times 10^{-6}$ ). Although many of the sex-specific genetic correlations 411 overlapped with those shared with sex-combined analysis, we also identified five traits with 412 statistically significant sex differences in their genetic correlation with HL. Four of them were 413 related to educational attainment with the strongest one observed for "Qualification: College or 414 *University degree*" (female rg=0.11, P= $2.52 \times 10^{-5}$ , male rg=-0.12, P= $1.15 \times 10^{-5}$ ; p<sub>sex-</sub> 415  $_{\text{difference}}=1.16\times10^{-9}$ ). The fifth genetic correlation was related to "*Time spend outdoors in summer*" 416 (female rg=-0.16, P= $2.73 \times 10^{-5}$ , male rg=0.06, P=0.08; p<sub>sex-difference</sub>= $1.95 \times 10^{-5}$ ). 417 418 To distinguish genetic correlations due to shared genetic mechanisms from those due to possible 419

420 cause-effect relationships, we conducted an LCV analysis, identifying 22 significant putative causal 421 effects ( $p < 5.68 \times 10^{-5}$ ; Figure 4, Supplemental Table 16).

422

The traits with putative causal effect on HL included psychiatric traits (e.g., "Ever had period of 423 mania / excitability" gcp=0.508, p= $3.59 \times 10^{-23}$ ), neurological disease (e.g., "Migraine" gcp=0.891, 424  $p=7.1\times10^{-21}$ ), gastrointestinal outcomes (e.g., "ICD-10 K63 Other diseases of intestine" gcp=0.884, 425  $p=2.25\times10^{-11}$ ), urogenital outcomes (e.g., "ICD-10 N32 Other disorders of bladder" gcp=0.755, 426  $p=7.83\times10^{-15}$ ), medication use (e.g., "*Ranitidine*" gcp=0.691, p=1.38×10^{-12}), cardiovascular 427 diseases ("Stroke family history" gcp=0.825, p= $6.67 \times 10^{-11}$ ), immunological conditions 428 ("*Eczema/dermatitis*" gcp=0.327, p= $3.82 \times 10^{-5}$ ), and workplace environment ("Workplace very") 429 *dusty*" gcp=0.733, p= $2.04 \times 10^{-10}$ ). We also identified genetic evidence that support a putative causal 430 role on HL for four outcomes: "*Tinnitus*" (gcp=0.705, p=4.85×10<sup>-8</sup>); "*I was easily distracted*" 431  $(gcp=0.069, p=8.44\times10^{-15})$ , and "Felt distant from other people in past month" (gcp=0.331,432  $p=6.52\times10^{-6}$ ). Although it did not survive multiple testing correction, the strongest sex difference 433 was observed with respect to "Not having bipolar or depression disorder" where there was a 434

435 negative genetic causal effect on HL in females but not in males (females gcp=-0.73, p=0.005; 436 males gcp=-0.28, p=0.147;  $p_{sex-difference}=7.69\times10^{-4}$ ).

437

## 438 Multivariate gene-by-environment genome-wide interaction analysis

To investigate the role of gene-environment interactions in the predisposition to HL, we conducted 439 a multivariate GEWIS. Because of the assumptions of the linear mixed model approach used<sup>50</sup>, we 440 conducted this analysis with respect to the HL-ORD trait (UKB N=300,818). We tested 14 441 environmental factors simultaneously (Supplemental Table 2). In addition to sex, these include 442 environments related to noise pollution (N=5) and tobacco smoking habits (N=8). Although no 443 444 variant survived genome-wide testing correction, we identified 1,278 LD-independent nominally significant multivariate interactions (Supplemental Table 17). To identify environment-specific 445 effects underlying the multivariate interactions of each of these variants, we considered BF>1 446 following StructLMM reccomendations<sup>50</sup>. We then conducted a GO enrichment analysis stratifying 447 the LD-independent loci with nominally significant multivariate interactions based on the 448 environment where they showed a BF>1. Considering FDR multiple testing correction at 5%, we 449 identified 204 significant enrichments with respect to 57 unique GO terms. Most GO enrichments 450 were shared across loci showing interaction effects with specific sex, noise, and smoking 451 452 environmental factors (BF>1). Specifically, loci with environment-specific interactions related to sex, noise, and smoking showed 17 shared GO enrichments with respect to (e.g., GO:0007399 453 Nervous system development: "Sex"  $p=2.0\times10^{-6}$ ; "Average evening sound level of noise pollution" 454  $p=1.3\times10^{-6}$ : "Maternal smoking around birth"  $p=3.6\times10^{-7}$ ). Similarly, loci interacting only with 455 noise and smoking environment (but not sex) shared 17 GO enrichments (e.g., GO:0030182 Neuron 456 differentiation: "Noisy workplace"  $p=4.4\times10^{-5}$ ; "Ever smoked"  $p=4.4\times10^{-6}$ ) and two GO 457 enrichments related to loci with environment-specific interactions related to sex and smoking (e.g., 458 GO:0050767 Regulation of neurogenesis: "Sex"  $p=7.5\times10^{-5}$ ; "Maternal smoking around birth" 459  $p=4.6\times10^{-5}$ ). We also identified enrichments related to loci interacting only with a specific 460

environment category: seven GO terms related to sex interactions (e.g., GO:0030857 Negative regulation of cell differentiation: "Sex" p= $8.2 \times 10^{-5}$ ), 10 GO terms related to noise-pollution interactions (e.g., GO:0050885 Neuromuscular process controlling balance: "Noisy workplace" p= $3.7 \times 10^{-4}$ ), and three GO terms related to smoking interactions (e.g., GO:0016101 Diterpenoid metabolic process: "Smoking/smokers in household" p= $2.1 \times 10^{-4}$ ).

- 466
- 467

### 468 **DISCUSSION**

We conducted a large-scale investigation integrating information from genome-wide associations with tissue-specific transcriptomic variation and a causal inference analysis to translate genetic findings into insights regarding HL biology and epidemiology. Additionally, we expanded the focus of our investigation to differences between sexes and ancestries and to the interplay of genetic variation with noise pollution and tobacco smoking, two well-known HL risk factors.

474

Initially, we compared the SNP-h<sup>2</sup> of different HL definitions available from UKB. These included 475 three questionnaire-derived self-reported hearing traits and one trait derived from audiometric 476 measures. Consistent with previous studies<sup>16,53</sup>, we observed that SRT-derived assessment had a 477 very low SNP-h<sup>2</sup> (<1%) that did not permit us to investigate further this HL outcome. Conversely, 478 self-reported HL outcomes showed significant SNP-h<sup>2</sup> that was informative to investigate their 479 polygenic architecture. We observed a high genetic correlation (rg>0.7) between them with the only 480 exception being "Hearing difficulty with background noise" and "Hearing aid use" where the 481 genetic correlation was much lower (rg<0.4). This may be because the proportion of individuals 482 who seek hearing aids for their hearing loss is very low, even in the UK where hearing aids are fully 483 covered by the National Health Service. Considering the HL outcome available in NHS and HPFS 484 cohorts, we observed the highest correlation with the UKB outcome "Hearing difficulties". 485 Accordingly, these traits were used for the GWAS meta-analysis and the subsequent in silico 486

investigations. These self-reported traits are considered relatively reliable instruments to investigate 487 "real world" hearing impairment, although potentially influenced by psycho-social factors<sup>16</sup>. 488 In the sex-combined GWAS meta-analysis including 501,825 individuals, we identified 54 LD-489 490 independent genome-wide significant associations, 14 of which are novel with respect to those identified by previous HL GWAS<sup>8,13,16,54</sup>. In the UKB-NHS-HPFS meta-analysis, three variants 491 showed statistical differences between sexes in their effect size. Specifically, rs13399656 in 492 SPTBN1 was the top findings in the sex-difference associations. This gene was previously 493 recognized as a target for  $\beta$ -estradiol as the top upstream regulator<sup>55</sup> and was already associated 494 with altered expression in estrogen-responsive tissues in HL<sup>8</sup>. Similarly, rs1808828 mapped to 495 496 ABLIM3 and rs11738813 in ARHGEF28 were identified as intronic variants mapped in genes involved in estrogen signaling pathway<sup>56,57</sup>. These sex-specific associations changes in significant 497 loci involved in hormonal regulating pathways may reflect the potential role of estrogen on hearing 498 499 functions.

500

Although this primary analysis was conducted in individuals of European descent, we replicated 501 several associations in an independent sample of 20,800 UKB participants of AFR, AMR, CSA, 502 EAS, and MID descent. Additionally, we demonstrated that HL polygenic risk is partially shared 503 across ancestry groups. However, consistent with previous studies of other health outcomes<sup>58–60</sup>, 504 505 there are large differences in the predictive power due to the genetic diversity across human populations. Additionally, in some cases the HL variance explained by the cross-ancestry PRS 506 association is larger than the one observed in the same-ancestry PRS association. This can be 507 explained by two factors: i) the cross-ancestry results are based on the UKB cohort where the 508 participants share the same HL assessment and sample characteristics; ii) the different LD structures 509 of the ancestries investigated may have inflated the results observed. 510

511

The fine-mapping of the risk loci led to identifying putatively pathogenic variants (CADD 512 513 score>10) mapped to genes previously demonstrated to be involved in HL pathogenesis. Specifically, we identified the exonic variant rs13147559 mapping in *CLRN2* as the strongest 514 finding (CADD=22.5). This locus has been identified as causative for non-syndromic HL<sup>61</sup> and may 515 have a role in hair cell mechano-transduction<sup>62</sup>. Two exonic mutations in *NOL12:TRIOBP* were 516 also identified as potentially deleterious (rs5756795 and rs7284476). TRIOBP alterations are related 517 to both congenital deafness<sup>63</sup> or Mendelian HL<sup>15</sup>. Mutations mapped to this gene have been 518 thoroughly analyzed, especially in patients with a post-lingual HL (i.e., HL occurring after the 519 development of normal speech)<sup>64,65</sup>. Non-coding regulatory variants were also identified in HL-520 521 related genes such as DLG4, ARID5B, and CTBP2. In mice, elevated Arid5b in the aged cochlea is known to be critical for the etiologies of sensorineural HL, such as age-related HL, noise- and 522 ototoxic drug-induced HL<sup>66</sup>. Conversely, *DLG4* was previously identified as significantly related to 523 hearing due to its association with the hippocampal glutamatergic synapse pathways<sup>67</sup>. The 524 deleterious variant mapping at CTBP2 also supports the role of the central nervous system in HL 525 526 pathogenesis. Indeed, CtBP2 is a marker for cochlear ribbon synapses, and deleterious variants (such as rs183893500, CADD=15.24) could influence vulnerability to cochlear synaptopathy (i.e., 527 loss of nerve connections between the sensory cells and the central nervous system) in acquired 528 sensorineural HL<sup>68,69</sup>. 529

530

Our TWAS further highlighted that HL genetic basis is partially linked to brain transcriptomic regulation. We identified that several genes previously implicated in HL pathogenesis because of their potential involvement in the peripheral structures of the auditory system, which also showed predicted expression differences in various brain regions. For example, while *CRIP3* has broad expression in inner and outer hair cells<sup>8</sup>, we observed that transcriptomic changes of this gene in the putamen basal ganglia were associated with HL. Similarly, other genes that may be implicated in HL pathogenesis through both peripheral and central mechanisms include *IPP* (previously reported

as highly expressed in human cochlear, cochlear hair cells, and spiral ganglion cells in mice<sup>54</sup>), 538 *PIK3R3* (previously identified as specific to cell types in the cochlea<sup>70</sup>). *MAST2* (showing 539 differential expression in the development of the inner ear<sup>54</sup>), and *SLC22A6* (identified as related to 540 cochlear impairment<sup>71</sup>). Taken together, these results suggest that auditory dysfunction is not 541 restricted to peripheral auditory structures, but subcortical neuroplastic changes involving the area 542 receiving ascending signals from inferior brainstem nuclei could also be involved<sup>72</sup>. Additionally, 543 several TWAS associations were related to the transcriptomic regulation in the cerebellum in line 544 with the involvement of this brain region in auditory pathways $^{73}$ . 545

546

547 The sex-stratified TWAS showed several additional associations related to peripheral tissues. In particular, the female-specific TWAS identified as top findings transcriptomic changes of genes in 548 breast mammary tissue (ABCC10) and vagina (BAIAP2L2). These associations in hormonally 549 regulated tissues may reflect a potential role of estrogen in hearing function<sup>74</sup>. Indeed, our sex-550 stratified analyses identified associations mapped in genes involved in the estrogen signaling 551 552 pathway (i.e., SPTBN1, ABLIM3, and ARHGEF28). With respect to the loci identified by the female-specific TWAS, BAIAP2L2 is particularly interesting. In mice, mutations of the homologous 553 gene Baiap2l2 were associated with alterations in hair cell transduction and deafness<sup>75</sup> while the 554 human locus BAIAP2L2 is associated with suppression of the estrogen-mediated S-phase entry 555 pathway in cell-cycle<sup>76</sup>. As the HL is associated with reduced estrogens levels, we hypothesize that 556 the interplay between BAIAP2L2 transcriptomic regulation and estrogen levels may play a role in 557 HL in women. 558

559

We leveraged the genome-wide association statistics generated by our sex-combined and sexstratified analyses to explore HL polygenic architecture in the context of other traits and diseases.
Our phenome-wide genetic correlation analysis identified a wide range of health outcomes that
share a significant proportion of their genetic liability with HL. The subsequent genetically-

informed causal inference analysis showed that some of these genetic correlations may be due to 564 565 cause-effect relationships linking HL to different health domains, including neurological, cardiovascular, and cancer-related outcomes. In line with the shared involvement of the auditory 566 system, the strongest HL genetic correlation was with tinnitus (i.e., the conscious perception of an 567 auditory sensation in the absence of a corresponding external stimulus<sup>77</sup>). This is consistent with the 568 strong association between tinnitus and HL in the elderly<sup>78</sup>. A previous Mendelian randomization 569 analysis showed a bidirectional relationship between them<sup>28</sup>. However, our LCV analysis supports 570 that HL may have a causal effect on tinnitus. Further studies will be needed to understand the 571 underlying dynamics of these comorbidities. 572

573

574 In addition, we observed several traits related to the psychological distress generally observed in 575 elderly individuals. They included positive genetic correlations with disability/infirmity and tiredness/lethargy and negative genetic correlations with the propensity to social activities and the 576 577 belief that life is meaningful. These findings illustrate that HL is associated with multiple aspects of quality of life in aging populations. We also identified five traits that showed statistically significant 578 sex differences in their correlation with HL. Four of them were related to educational attainment 579 where the genetic correlation with HL was positive in females and negative in males. A previous 580 581 study demonstrated that the characteristics and the recruitment strategy of the UKB cohort (the 582 largest sample in our meta-analysis) influenced some of the sex differences observable in this study population<sup>79</sup>. Accordingly, this sex difference may be specific to the structure of the UKB cohort. 583 The other sex difference was related to time spent outside that showed a negative genetic 584 correlation in females but not in males. This could be related to the higher comorbidity of HL with 585 depression observed in women compared to men<sup>80</sup>. 586

587

Finally, our multivariate GEWIS analysis explored the interplay of genetic variation with sex
differences and two established HL risk factors, noise pollution and tobacco smoking. Although no

single interactive locus remained statistically significant after multiple testing correction, we 590 591 observed several biological processes that are potentially involved in the inter-individual susceptibility to the effects of HL environmental risk factors. Loci interacting with sex, noise, and 592 smoking environmental factors were mostly enriched for the same molecular pathways, suggesting 593 594 that HL environmental risk factors may affect the same biological processes that lead to the onset of the diseases. In particular, we observed an overrepresentation of pathways related to brain 595 596 developmental processes. An intriguing finding was the observed higher risk of HL with maternal smoking around birth, suggesting that early life exposures may influence later life auditory 597 function. 598

599

600 Although our findings advance our understanding of HL and its consequences in adults, we also acknowledge several limitations. Similar to previous HL GWAS<sup>8,13–16</sup>, our primary analyses were 601 based on self-reported data. These appear to be more informative than the audiometric measures 602 603 derived from SRT test, but they can still be biased by misreporting linked to cognitive processes, social desirability, and survey conditions. Our study was focused on acquired HL in adults and we 604 excluded individuals with congenital HL when possible. However, we did not have information 605 regarding HL age of onset across all cohorts investigated. Accordingly, a small proportion (<1%) of 606 607 congenital HL cases may be present in our study populations. No sex-specific TWAS models are 608 currently available from GTEx. Accordingly, our sex-stratified TWAS was conducted using sexstratified genome-wide association statistics and sex-combined transcriptomic reference panels. 609 This has likely reduced the statistical power of our analysis. Additionally, GTEx does not include 610 tissues related to peripheral auditory system, limiting our ability to explore the differences in 611 transcriptomic changes in the peripheral and central auditory system. Although we investigated 612 cross-ancestry transferability of HL genetic risk, the limited diversity of the cohorts investigated did 613 not permit us to explore the genetic basis of HL across ancestry groups. Similar to what observed 614

for other complex traits, HL PRS explained a small phenotypic variance when applied across
cohorts (e.g., the PRS derived from UKB-NHS-HPFS meta-analysis and applied to MVP sample).

In conclusion, we conducted a comprehensive investigation of the polygenic architecture of HL that i) identified novel risk loci, ii) provided evidence of the shared HL pathogenesis across human populations, iii) integrated genetic and transcriptomic data to dissect HL biology, iv) leveraged genome-wide information to explore the mechanisms underlying HL comorbidities, and v) uncovered possible biological processes that could underlie inter-individual differences in susceptibility to the effects of HL environmental risk factors. Further studies will be needed to translate this information into tools useful to improve HL preventive and therapeutic strategies.

625

#### 626 ACKNOWLEDGEMENTS

This research is funded by the National Institute on Deafness and Other Communication Disorders 627 (R21 DC018098, UO1 DC010811). The authors also acknowledge grants from the National 628 Institute on Drug Abuse (R33 DA047527), the National Institute on Mental Health (F32 629 MH122058), the National Cancer Institute (UM1 CA186107, UO1 CA167552, and UO1 630 CA176726), the One Mind, and the Marie Sklodowska-Curie Actions (Individual Fellowship 631 101028810). This research was performed using the UK Biobank Resource under the application 632 633 58146. This research is also based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award #MVP010. This 634 publication does not represent the views of the Department of Veteran Affairs or the United States 635 636 Government. We thank all the participants in the UK Biobank, the Nurse's Health Studies, the Health Professionals Follow-up Study, and the Million Veteran Program. 637 638

### 639 COMPETING INTERESTS

- 640 Dr Clifford reported receiving personal fees from Decibel Therapeutics outside the submitted work.
- 641 Dr. S. Curhan serves as a consultant to Decibel Therapeutics. Dr. G. Curhan serves as a consultant
- to Decibel Therapeutics, AstraZeneca, Shire, Allena Pharmaceuticals, RenalGuard, OrfanBiotech,
- 643 OM1, and Merck. He receives royalties from UpToDate for being an author and Section Editor.
- None of the other authors declare any competing interests.
- 645

#### 646 **REFERENCES**

- 1. Masterson, E. A. Hearing Impairment Among Noise-Exposed Workers United States, 2003–
  2012. *MMWR Morb. Mortal. Wkly. Rep.* 65, (2016).
- 649 2. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and
- national incidence, prevalence, and years lived with disability for 310 diseases and injuries,
- 651 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Lond*.
- 652 *Engl.* **388**, 1545–1602 (2016).
- 653 3. World Report on Hearing. https://www.who.int/teams/noncommunicable-diseases/sensory-
- 654 functions-disability-and-rehabilitation/highlighting-priorities-for-ear-and-hearing-care.
- 4. Deal, J. A. *et al.* Incident Hearing Loss and Comorbidity: A Longitudinal Administrative Claims
  Study. *JAMA Otolaryngol. Neck Surg.* 145, 36–43 (2019).
- 5. Shukla, A. *et al.* Hearing Loss, Loneliness, and Social Isolation: A Systematic Review.
- Otolaryngol.--Head Neck Surg. Off. J. Am. Acad. Otolaryngol.-Head Neck Surg. 162, 622–633
  (2020).
- 660 6. Malcolm, M., Frost, H. & Cowie, J. Loneliness and social isolation causal association with
- health-related lifestyle risk in older adults: a systematic review and meta-analysis protocol. *Syst. Rev.* 8, 48 (2019).
- 663 7. Nicolson, T. Navigating Hereditary Hearing Loss: Pathology of the Inner Ear. Front. Cell.
- 664 *Neurosci.* **15**, 184 (2021).

- 665 8. Praveen, K. et al. Population-scale analysis of common and rare genetic variation associated
- *with hearing loss in adults*. http://medrxiv.org/lookup/doi/10.1101/2021.09.27.21264091 (2021)
  doi:10.1101/2021.09.27.21264091.
- 668 9. Cunningham, L. L. & Tucci, D. L. Hearing Loss in Adults. N. Engl. J. Med. 377, 2465–2473
- (2017).
- Hayashi, K., Suzuki, Y., Fujimoto, C. & Kanzaki, S. Molecular Mechanisms and Biological
  Functions of Autophagy for Genetics of Hearing Impairment. *Genes* 11, 1331 (2020).
- 11. Zhang, L. *et al.* THOC1 deficiency leads to late-onset nonsyndromic hearing loss through
- 673 p53-mediated hair cell apoptosis. *PLOS Genet.* **16**, e1008953 (2020).
- 12. Zhang, W. *et al.* Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and
- 675 Major Remaining Hurdles for Translational Success. *Front. Mol. Neurosci.* **11**, 221 (2018).
- 13. Hoffmann, T. J. et al. A Large Genome-Wide Association Study of Age-Related Hearing
- Impairment Using Electronic Health Records. *PLoS Genet.* **12**, e1006371 (2016).
- 14. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide
- range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
- Kalra, G. *et al.* Biological insights from multi-omic analysis of 31 genomic risk loci for
  adult hearing difficulty. *PLOS Genet.* 16, e1009025 (2020).
- 16. Wells, H. R. R. et al. GWAS Identifies 44 Independent Associated Genomic Loci for Self-
- Reported Adult Hearing Difficulty in UK Biobank. Am. J. Hum. Genet. 105, 788–802 (2019).
- 17. Villavisanis, D. F., Berson, E. R., Lauer, A. M., Cosetti, M. K. & Schrode, K. M. Sex-Based
- 685Differences in Hearing Loss: Perspectives from Non-Clinical Research to Clinical Outcomes.
- 686 Otol. Neurotol. Off. Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol. 41, 290–
- 687 298 (2020).
- 18. Nolan, L. S. Age-related hearing loss: Why we need to think about sex as a biological
- 689 variable. J. Neurosci. Res. 98, 1705–1720 (2020).

- Ma, J., Li, C., Kwan, M.-P., Kou, L. & Chai, Y. Assessing personal noise exposure and its
  relationship with mental health in Beijing based on individuals' space-time behavior. *Environ. Int.* 139, 105737 (2020).
- 693 20. Polimanti, R., Jensen, K. P. & Gelernter, J. Phenome-wide association study for CYP2A6
- alleles: rs113288603 is associated with hearing loss symptoms in elderly smokers. *Sci. Rep.* **7**,
- 695 1034 (2017).
- Agrawal, Y., Platz, E. A. & Niparko, J. K. Prevalence of hearing loss and differences by
  demographic characteristics among US adults: data from the National Health and Nutrition
- Examination Survey, 1999-2004. Arch. Intern. Med. 168, 1522–1530 (2008).
- Lin, B. M. *et al.* Cigarette Smoking, Smoking Cessation, and Risk of Hearing Loss in
  Women. *Am. J. Med.* 133, 1180–1186 (2020).
- 701 23. Colditz, G. A., Manson, J. E. & Hankinson, S. E. The Nurses' Health Study: 20-year
- contribution to the understanding of health among women. J. Womens Health 6, 49–62 (1997).
- 703 24. Tworoger, S. S., Sluss, P. & Hankinson, S. E. Association between plasma prolactin
- concentrations and risk of breast cancer among predominately premenopausal women. *Cancer*
- 705 *Res.* **66**, 2476–2482 (2006).
- Rimm, E. B. *et al.* Prospective study of alcohol consumption and risk of coronary disease in
  men. *Lancet Lond. Engl.* 338, 464–468 (1991).
- 708 26. Gaziano, J. M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences
  709 on health and disease. *J. Clin. Epidemiol.* **70**, 214–223 (2016).
- Public Health 106, 1573–1581 (2016).
  27. Bao, Y. *et al.* Origin, Methods, and Evolution of the Three Nurses' Health Studies. *Am. J.*
- 712 28. Clifford, R. E., Maihofer, A. X., Stein, M. B., Ryan, A. F. & Nievergelt, C. M. Novel Risk
- Loci in Tinnitus and Causal Inference With Neuropsychiatric Disorders Among Adults of
- European Ancestry. *JAMA Otolaryngol.-- Head Neck Surg.* **146**, 1015–1025 (2020).

- 715 29. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
- 716 *Nature* **562**, 203–209 (2018).
- 717 30. Lindström, S. et al. A comprehensive survey of genetic variation in 20,691 subjects from

four large cohorts. *PLOS ONE* **12**, e0173997 (2017).

- 719 31. Ware, E. B. *et al.* Genome-wide Association Study of 24-Hour Urinary Excretion of
- Calcium, Magnesium, and Uric Acid. *Mayo Clin. Proc. Innov. Qual. Outcomes* **3**, 448–460
- 721 (2019).
- 32. Hunter-Zinck, H. *et al.* Genotyping Array Design and Data Quality Control in the Million
  Veteran Program. *Am. J. Hum. Genet.* 106, 535–548 (2020).
- 33. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.
- 725 Bioinforma. Oxf. Engl. 26, 2867–2873 (2010).
- 726 34. Fang, H. et al. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in
- Genome-wide Association Studies. Am. J. Hum. Genet. 105, 763–772 (2019).
- 35. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
  datasets. *GigaScience* 4, (2015).
- 730 36. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
- genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 732 37. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
- polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
  association summary statistics. *Nat. Genet.* 47, 1228–1235 (2015).
- 736 39. Gazal, S., Marquez-Luna, C., Finucane, H. K. & Price, A. L. Reconciling S-LDSC and
- T37 LDAK functional enrichment estimates. *Nat. Genet.* **51**, 1202–1204 (2019).
- 40. Wendt, F. R. et al. Characterizing the effect of background selection on the polygenicity of
- 739 brain-related traits. *Genomics* **113**, 111–119 (2021).

- 41. O'Connor, L. J. & Price, A. L. Distinguishing genetic correlation from causation across 52
- 741 diseases and complex traits. *Nat. Genet.* **50**, 1728–1734 (2018).
- 42. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
- annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
- 43. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the
- deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 47, D886–D894
- 746 (2019).
- 44. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set
- Analysis of GWAS Data. *PLOS Comput. Biol.* **11**, e1004219 (2015).
- 749 45. THE GTEX CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects
- across human tissues. *Science* **369**, 1318–1330 (2020).
- 46. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
- selection in regression, with application to genetic fine mapping. J. R. Stat. Soc. Ser. B Stat.
- 753 *Methodol.* **82**, 1273–1300 (2020).
- 47. Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues improves
  association detection. *PLoS Genet.* 15, e1007889 (2019).
- 48. Choi, S. W. & O'Reilly, P. F. PRSice-2: Polygenic Risk Score software for biobank-scale
  data. *GigaScience* 8, (2019).
- Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk
  score analyses. *Nat. Protoc.* (2020) doi:10.1038/s41596-020-0353-1.
- 50. Moore, R. et al. A linear mixed model approach to study multivariate gene-environment
- 761 interactions. *Nat. Genet.* **51**, 180–186 (2019).
- 762 51. Howe, K. L. et al. Ensembl 2021. Nucleic Acids Res. 49, D884–D891 (2021).
- 52. Jiao, X. *et al.* DAVID-WS: a stateful web service to facilitate gene/protein list analysis.
- 764 *Bioinformatics* **28**, 1805–1806 (2012).

- 53. Cherny, S. S. *et al.* Self-reported hearing loss questions provide a good measure for genetic
- studies: a polygenic risk score analysis from UK Biobank. *Eur. J. Hum. Genet.* 28, 1056–1065
  (2020).
- 768 54. Nagtegaal, A. P. *et al.* Genome-wide association meta-analysis identifies five novel loci for
  769 age-related hearing impairment. *Sci. Rep.* 9, 15192 (2019).
- 55. Youngblood, H. A. et al. Identification of Estrogen Signaling in a Prioritization Study of
- Intraocular Pressure-Associated Genes. Int. J. Mol. Sci. 22, 10288 (2021).
- 56. Wu, J.-R., Zhao, Y., Zhou, X.-P. & Qin, X. Estrogen receptor 1 and progesterone receptor
- are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer:
- Evidence from a bioinformatic analysis. *Biomed. Pharmacother.* **121**, 109647 (2020).
- 57. Wardell, S. E., Nelson, E. R., Chao, C. A. & McDonnell, D. P. Bazedoxifene Exhibits
- Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications
  for Treatment of Advanced Disease. *Clin. Cancer Res.* 19, 2420–2431 (2013).
- 58. Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic
  Studies. *Cell* 177, 26–31 (2019).
- 59. Rosenberg, N. A., Edge, M. D., Pritchard, J. K. & Feldman, M. W. Interpreting polygenic
- scores, polygenic adaptation, and human phenotypic differences. *Evol. Med. Public Health* 2019,
  26–34 (2019).
- 60. Duncan, L. *et al.* Analysis of polygenic risk score usage and performance in diverse human
  populations. *Nat. Commun.* 10, 3328 (2019).
- 785 61. Vona, B. *et al.* A biallelic variant in CLRN2 causes non-syndromic hearing loss in humans. *Hum. Genet.* 140, 915–931 (2021).
- Dunbar, L. A. *et al.* Clarin- 2 is essential for hearing by maintaining stereocilia integrity and
  function. *EMBO Mol. Med.* 11, e10288 (2019).
- 789 63. Zhou, B. et al. A novel mutation in TRIOBP gene leading to congenital deafness in a
- 790 Chinese family. *BMC Med. Genet.* **21**, 121 (2020).

- Kochhar, A., Hildebrand, M. S. & Smith, R. J. H. Clinical aspects of hereditary hearing loss. *Genet. Med.* 9, 393–408 (2007).
- 793 65. Pollak, A. *et al.* Whole exome sequencing identifies TRIOBP pathogenic variants as a cause
- of post-lingual bilateral moderate-to-severe sensorineural hearing loss. *BMC Med. Genet.* **18**, 142
- 795 (2017).
- 796 66. Fujimoto, C. & Yamasoba, T. Mitochondria-Targeted Antioxidants for Treatment of
- Hearing Loss: A Systematic Review. *Antioxidants* **8**, 109 (2019).
- 798 67. Deng, T. et al. Hippocampal Transcriptome-Wide Association Study Reveals Correlations
- 799 Between Impaired Glutamatergic Synapse Pathway and Age-Related Hearing Loss in BXD-
- 800 Recombinant Inbred Mice. *Front. Neurosci.* **15**, 1356 (2021).
- 68. Liberman, M. C. & Kujawa, S. G. Cochlear synaptopathy in acquired sensorineural hearing
  loss: Manifestations and mechanisms. *Hear. Res.* 349, 138–147 (2017).
- Kiong, W., Yu, S., Liu, K. & Gong, S. Loss of cochlear ribbon synapses in the early stage of
  aging causes initial hearing impairment. *Am. J. Transl. Res.* 12, 7354–7366 (2020).
- 805 70. Xue, N. et al. Genes related to SNPs identified by Genome-wide association studies of age-
- related hearing loss show restriction to specific cell types in the adult mouse cochlea. *Hear. Res.*410, 108347 (2021).
- Fitzakerley, J. L. & Trachte, G. J. Genetics of guanylyl cyclase pathways in the cochlea and
  their influence on hearing. *Physiol. Genomics* 50, 780–806 (2018).
- 810 72. Qu, H., Tang, H., Pan, J., Zhao, Y. & Wang, W. Alteration of Cortical and Subcortical
  811 Structures in Children With Profound Sensorineural Hearing Loss. *Front. Hum. Neurosci.* 14,
- **812 534** (2020).
- 813 73. Llano, D. A., Kwok, S. S., Devanarayan, V. & The Alzheimer's Disease Neuroimaging
- 814 Initiative (ADNI). Reported Hearing Loss in Alzheimer's Disease Is Associated With Loss of
- Brainstem and Cerebellar Volume. *Front. Hum. Neurosci.* **15**, 562 (2021).

- 816 74. Simonoska, R. *et al.* Inner ear pathology and loss of hearing in estrogen receptor-β deficient
- 817 mice. J. Endocrinol. 201, 397–406 (2009).
- 818 75. Carlton, A. J. et al. Loss of Baiap212 destabilizes the transducing stereocilia of cochlear hair
- cells and leads to deafness. J. Physiol. **599**, 1173–1198 (2021).
- 820 76. Xu, L. *et al.* BAI1<sup>-</sup> associated protein 2<sup>-</sup> like 2 is a potential biomarker in lung cancer.
- 821 *Oncol. Rep.* **41**, 1304–1312 (2019).
- 822 77. Baguley, D., McFerran, D. & Hall, D. Tinnitus. *Lancet Lond. Engl.* **382**, 1600–1607 (2013).
- 823 78. Biswas, R. *et al.* Tinnitus prevalence in Europe: a multi-country cross-sectional population
- study. Lancet Reg. Health Eur.  $\mathbf{0}$ , (2021).
- 825 79. Pirastu, N. *et al.* Genetic analyses identify widespread sex-differential participation bias.
- 826 Nat. Genet. 53, 663–671 (2021).
- 827 80. Scinicariello, F. *et al.* Age and sex differences in hearing loss association with depressive
- symptoms: analyses of NHANES 2011-2012. *Psychol. Med.* **49**, 962–968 (2019).
- 829
- 830

# 831 Figure Legends

Figure 1: Genetic correlation among hearing loss traits assessed via questionnaire in UK Biobank.The square shade intensity is proportional to the magnitude of the correlation.

**Figure 2**: Multi-tissue transcriptome-wide association study of hearing loss based on the sexcombined meta-analysis. The y-axis corresponds to two-tailed  $-\log 10$  (p-value of the S-MultiXcan association). The x-axis reports the genes grouped based on the best single-tissue S-PrediXcan association. The red line refers to the Bonferroni multiple testing correction accounting for the number of genes tested (p<2.24×10<sup>-6</sup>). Bold labels are reported for the top-10 Bonferroni significant association. Additional labels are included for the top significant result for each tissue. Detailed results are available in Supplemental Table 12.

**Figure 3**: Phenome-wide genetic correlation of hearing loss in the sex-combined analysis. The xaxis reports the genetic correlation of hearing loss with the traits tested. The y-axis corresponds to two-tailed  $-\log_{10}(p-value)$ . Blue shades correspond to significance strength, from white, nonsignificant (p>0.05), to light blue (nominal significance p<0.05), to blue (Bonferroni correction p<9×10-6), and dark blue (top 10 results). Phenotype labels are included for the top 10 results. Full results are reported in Supplemental Table 15.

Figure 4: Visual representation of the 22 significant putative causal effects identified through the
latent causal variable analysis. Brown labels: HL has causative effect for the trait in the label;
Purple labels: Trait in the label has causative effect for HL. The absolute gcp (genetic causality
proportion) value for each association is reported within the arrow, and the directions refer to the
cause-effect relationship (Blue: HL causes Trait; Red: Trait causes HL). The shade intensity of the
arrows is proportional to the statistical significance of the gcp estimates. Description of each trait
tested, and details of the associations is available in Supplemental Table 16.

- Supplemental Figure 1: Visual representation of the fine-mapping analysis for sex-combined
  meta-analysis. Each panel refers to a GWS risk locus. The variants were identified according to
  their LD with respect to the lead SNP and inclusion in the credible set with at most ten causal
  variants.
- Supplemental Figure 2: Visual representation of the fine-mapping analysis for female metaanalysis. Each panel refers to a GWS risk locus. The variants were identified according to their LD
  with respect to the lead SNP and inclusion in the credible set with at most ten causal variants.
- Supplemental Figure 3: Visual representation of the fine-mapping analysis for male meta-analysis.
  Each panel refers to a GWS risk locus. The variants were identified according to their LD with
  respect to the lead SNP and inclusion in the credible set with at most ten causal variants.
- 864
- 865
- 866
- 867
- 868







# **Best single-tissue S-PrediXcan association**

- Adipose
- Breast
- Heart
- Salivary Gland
- Pancreas
- Small Intestine
- Thyroid

- Adrenal Gland
- Cells
- Kidney
- Skeletal Muscle
- Pituitary Gland
- Spleen
- Uterus

- Artery
- Colon
- Liver
- Tibial Nerve
- Prostate
- Stomach
- Vagina

- Brain
- Esophagus
- Lung
- Ovary
- Skin
- Testis
- Whole Blood





# Table 1: SNP heritability (SNP-h<sup>2</sup>) of hearing loss related traits assessed in the UK

**Biobank.** SE: standard error.

Analysis	Trait	Ν	SNP- h <sup>2</sup>	SE	SNP-h <sup>2</sup> Z-score
	Hearing difficulty/problems	465,782 (125,011 cases and 340,771 controls)	0.038	0.002	20.16
Sex-	Hearing difficulty/problems with background noise	476,031 (183,497 cases and 292.534 controls)	0.050	0.002	26.11
combined	Hearing aid user	321,577 (17,754 cases and 303,823 controls)	0.017	0.002	9.67
	Speech-reception-threshold (SRT) estimate (left)	195,188	0.002	0.002	0.96
	Speech-reception-threshold (SRT) estimate (right)	195,916	0.009	0.002	3.74
	Hearing loss ordinal trait	300,818	0.045	0.003	15.23
	Hearing difficulty/problems	214,549 (68,781 cases and 145,768 controls)	0.048	0.003	15.45
Males	Hearing difficulty/problems with background noise	218,106 (97,002 cases and 121,104 controls)	0.050	0.003	16.23
	Hearing aid user	156,017 (9,882 cases and 146,135 controls)	0.021	0.003	6.59
	Hearing loss ordinal trait	147,719	0.051	0.004	12.73
	Hearing difficulty/problems	251,233 (56,230 cases and 195,003 controls)	0.040	0.003	14.21
Females	Hearing difficulty/problems with background noise	257,925 (86,495 cases and 171,430 controls)	0.054	0.003	18.79
	Hearing aid user	165,560 (7,872 cases and 157,688 controls)	0.017	0.003	5.55
	Hearing loss ordinal trait	153,099	0.054	0.004	13.5

**Table 2: LD-independent loci associated with hearing difficulties reaching genome-wide significance (p<5×10<sup>-8</sup>) in the meta-analysis of UK Biobank (UKB), Nurses' Health Studies (NHS; I and II), and Health Professional Follow-up Study (HPFS). The results of the replication analysis in Million Veteran Program (MVP) are also reported. Abbreviations: chromosome (CHR), position (POS); base pairs (bp); Effect Allele Frequency (EAF); Odds Ratio (OR), P value (P).** 

			T.ff. of	Other	UKB-NHS-HPFS		MVP	
rsID	CHR	POS (bp)	Allele	Allele	meta-analysis		Replication	
					OR	Р	OR	Р
rs36062310	22	50,988,105	А	G	1.15	2.75×10 <sup>-32</sup>	1.08	4.80×10 <sup>-6</sup>
rs6871548	5	73,076,024	Т	C	1.05	2.30×10 <sup>-25</sup>	1.04	1.23×10 <sup>-8</sup>
rs34993346	11	89,046,097	A	G	0.95	1.38×10 <sup>-24</sup>	1.00	0.872
rs2254303	6	43,276,390	A	G	1.05	1.19×10 <sup>-23</sup>	1.04	5.23×10 <sup>-11</sup>
rs10901863	10	126,812,270	Т	C	1.05	6.21×10 <sup>-23</sup>	1.06	1.17×10 <sup>-11</sup>
rs739138	22	38,122,462	Α	G	0.95	4.70×10 <sup>-19</sup>	0.96	6.21×10 <sup>-8</sup>
rs67307131	11	118,480,223	Т	C	0.96	3.12×10 <sup>-18</sup>	0.97	2.83×10 <sup>-7</sup>
rs9493627	6	133,789,728	Α	G	1.04	1.03×10 <sup>-17</sup>	1.06	1.91×10 <sup>-19</sup>
rs11073804	15	89,252,012	А	Т	0.95	5.60×10 <sup>-17</sup>	0.91	3.50×10 <sup>-28</sup>
rs6662164	1	46,146,230	А	Т	1.04	6.59×10 <sup>-17</sup>	1.04	7.44×10 <sup>-9</sup>
rs72622588	3	182,003,490	Т	G	0.95	1.53×10 <sup>-16</sup>	0.97	0.002
rs1566128	14	52,514,981	А	G	1.04	$1.02 \times 10^{-15}$	1.04	3.98×10 <sup>-11</sup>
rs6545432	2	54,817,683	А	G	1.04	1.05×10 <sup>-15</sup>	1.04	2.37×10 <sup>-8</sup>
rs11041717	11	8,054,933	Α	C	0.96	7.31×10 <sup>-15</sup>	0.98	0.071
rs2877561	3	121,712,051	А	C	1.04	$1.62 \times 10^{-14}$	1.03	4.95×10 <sup>-4</sup>
rs13147559	4	17,524,570	С	G	0.95	3.81×10 <sup>-14</sup>	0.99	0.596
rs2296506	6	158,507,981	А	G	1.03	1.70×10 <sup>-13</sup>	1.02	3.36×10 <sup>-4</sup>
rs13171669	5	148,601,243	А	G	0.97	1.15×10 <sup>-12</sup>	0.98	0.007
rs12156228	8	141,701,299	Т	G	0.97	3.67×10 <sup>-12</sup>	0.97	6.31×10 <sup>-4</sup>
rs222836	17	7,133,162	А	G	0.97	1.13×10 <sup>-11</sup>	0.98	7.37×10 <sup>-4</sup>
rs4948502	10	63,839,417	Т	C	1.03	1.26×10 <sup>-11</sup>	1.01	0.229
rs11238325	7	50,853,151	Т	C	1.04	$1.88 \times 10^{-11}$	1.04	5.65×10 <sup>-6</sup>
rs35094336	8	82,670,771	Α	G	1.06	2.07×10 <sup>-11</sup>	1.03	0.021
rs7712395	5	2,559,538	Т	C	1.05	3.64×10 <sup>-11</sup>	1.04	6.45×10 <sup>-5</sup>
rs143282422	10	73,377,112	А	G	1.16	4.43×10 <sup>-11</sup>	1.22	8.30×10 <sup>-11</sup>
rs6675438	1	165,112,224	А	Т	1.03	8.82×10 <sup>-11</sup>	1.03	1.62×10 <sup>-4</sup>
rs57167368	10	80,521,351	А	G	0.96	9.91×10 <sup>-11</sup>	0.97	0.001
rs72930998	18	52,632,968	Т	C	0.97	2.03×10 <sup>-10</sup>	0.98	0.028
rs1171114	6	84,227,646	Т	C	0.97	2.69×10 <sup>-10</sup>	0.98	0.018
rs2354376	7	138,487,145	А	C	1.03	3.17×10 <sup>-10</sup>	1.01	0.100
rs717973	2	208,091,112	А	G	0.97	4.61×10 <sup>-10</sup>	0.99	0.072
rs7819550	8	74,206,582	А	G	1.04	6.96×10 <sup>-10</sup>	1.05	3.92×10 <sup>-9</sup>
rs72818515	10	76,060,718	А	C	1.03	$7.08 \times 10^{-10}$	1.01	0.186
rs112725535	1	6,494,086	Α	G	0.96	$7.85 \times 10^{-10}$	0.99	0.318

rs11022697	11	13,178,285	C	G	0.97	1.17×10 <sup>-9</sup>	0.97	1.15×10 <sup>-5</sup>
rs34073570	5	103,998,895	СТ	С	0.97	1.32×10 <sup>-9</sup>	0.99	0.316
rs61863078	10	94,777,108	A	G	1.03	1.54×10 <sup>-9</sup>	1.00	0.777
rs111935448	16	30,919,807	Т	С	1.04	1.75×10 <sup>-9</sup>	0.99	0.218
rs58919600	5	92,970,519	Т	С	1.04	1.86×10 <sup>-9</sup>	1.03	0.002
rs11085064	19	4,209,152	A	G	1.04	2.84×10 <sup>-9</sup>	1.03	9.49×10 <sup>-4</sup>
rs9783279	11	68,972,992	A	С	0.97	2.97×10 <sup>-9</sup>	1.00	0.872
rs8102051	19	2,370,476	A	С	1.03	3.38×10 <sup>-9</sup>	1.01	0.429
rs5800853	12	109,790,748	CAG	С	1.03	4.87×10 <sup>-9</sup>	1.02	0.017
rs1928176	6	21,968,899	A	G	0.97	5.44×10 <sup>-9</sup>	0.99	0.028
rs9530470	13	76,416,638	A	G	0.97	5.64×10 <sup>-9</sup>	0.99	0.051
rs148512269	2	227,596,034	Т	G	1.11	9.83×10 <sup>-9</sup>	1.05	0.133
rs61734651	20	61,451,332	Т	С	1.06	1.30×10 <sup>-8</sup>	1.03	0.028
rs8063057	16	53,812,433	Т	С	1.03	1.64×10 <sup>-8</sup>	1.01	0.081
rs566673	11	66,401,373	Т	G	0.97	1.80×10 <sup>-8</sup>	1.01	0.277
rs78229182	6	151128784	Т	С	1.05	2.07×10 <sup>-8</sup>	0.98	0.106
rs73204028	7	115,092,852	Т	С	0.97	2.20×10 <sup>-8</sup>	0.98	0.012
rs766262445 (MVP LD-proxy: rs9536378)	13	53,830,039	CT(A)	С	1.03	2.63×10 <sup>-8</sup>	1.00	0.787
rs2273654	10	102,689,217	Т	С	0.97	4.01×10 <sup>-8</sup>	0.99	0.425
rs35624969	7	72,991,592	Т	С	0.97	4.66×10 <sup>-8</sup>	0.99	0.218